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目前现有的研究证实，抗 DR5 单克隆抗体 (aDR5mAb) 可通过与 DR5 的特异








本实验室构建了抗 DR5 单链抗体（aDR5scFv），通过 ELISA 方法对单链抗体进
行了特异性分析。通过 MTT 法检测 aDR5scFv 对肺腺癌细胞 973 的细胞毒效应；
流式细胞术检测 aDR5scFv 诱导 973 的凋亡率； Western blot 检测 Bax，caspase-3，
细胞色素 c 的蛋白表达；为了研究体内 aDR5scFv 对肺腺癌的作用，我们应用 973
细胞建立了裸鼠肺腺癌模型，腹腔注射给药，并联合放射治疗，观察 aDR5scFv 的体
内抑瘤效果，通过 HE 染色和 TUNEL 分析其可能机制。 
结果 















973 细胞生长呈剂量依赖性，aDR5scFv 终浓度分别为 0.225，0.45，0.9，1.2  mg/
mL 应用 200 μL  时，对 973 细胞的生长抑制率分别为 28.8%，52.3%，65.3%，
89.8%；与流式细胞术检测结果相符。Western blot 检测到 aDR5scFv 作用细胞 4h 
后 Bax，caspase-3，细胞色素 c 蛋白表达上调。 
体内实验观察到 aDR5scFv 实验组与空白组相比，肿瘤体积明显减小，并观察
到 aDR5scFv 与放疗联合应用时，肿瘤体积明显小于单独应用组。Tunel 及 HE 染
色发现 aDR5scFv 与放疗联合应用组凋亡明显强于单独应用组。 
结论 
1. aDR5scFv 能够特异结合 eDR5 ； 
2.体外实验表明 aDR5scFv 抑制肺腺癌 973 细胞生长与 Bax，caspase-3 及细胞
色素 c 表达上调相关； 
3.体内实验表明 aDR5scFv 能够抑制 973 细胞生长，并且对正常肝细胞无毒性
作用。 aDR5scFv 与放疗联合应用组明显强于单独应用组。 

















Background & objective 
Lung cancer is one of common malignant tumors in the world。There are two kinds of 
Lung cancer.One is SCLC.The other is NSCLC. The number of people who suffer from 
NSCLC accounted for most of the number of people who have Lung cancar It's about 80 
pecent.About 65%~70% of NSCLC are found to be in the advanced stage.Althought the 
expectation of patients who have SCLC in early stage is almost good, the expectation of 
most patient who have NSCLC in advanced stage is not so good。Immuntherapy is a new 
therapy which is not popular in clinical ,but it is a potencial therapy. 
Today, reseach have confirm that aDR5mAb can recognise DR5 specifically and 
induce the apoptosis of cells which express DR5; but there was some report about 
aDR5mAb responsible for the cytotoxicity in hepatocytes .So far most aDR5mAb are 
mouse aDR5mAb .It will be rejected by human .and its power decline .therefore ,most 
people choose to chang the stracture of aDR5mAb .We have produce aDR5mAb ,and we 
confirm that it can induce apotosis in tumor cells with no untoward effects on hepatocytes . 
We have obtain the heavy chain and light chain of aDR5mAb and construct 
aDR5scFv .Aim to know the power of aDR5scFv ,we have planed expriments which can 
help us to know the characterization of aDR5scFv ,its ability that induce apoptosis in 
tumor cells in vitro and in vivo . 
METHOD 
Our laboratory had constructed aDR5scFv. aDR5scFv could recognize eDR5 
specifically.It was confirmed by ELISA. We empLoyed MTT assay to detect the 
aDR5scFv cytotoxicity against 973 cell. Bax, Cyto c and caspase-3 ,such proteins which 
expression in aDR5scFv-treated 973 cells are detected by western blot . 
. In order to know wether aDR5scFv can induce 973 cell apoptosis in vivo,first,we 















that,I administrated aDR5scFv to those nude rats’ lung cancer animal model using 
intraperitoneal injection for the sake of finding out the variation of rat's tumor volume . I 
harvest the tumor of the rats and weight it .. HE staining and TUNEL assay for the tumor 
tissue were performed to detect apoptosis. 
RESULT 
During the research process,I was observing the phenomenon that aDR5scFv could 
recognize eDR5 specifically; aDR5scFv inhibited the growth of 973 cells in a 
dose-dependent manner (aDR5scFv final concentrations of 0.225, 0.45, 0.9, 1.2 mg/mL 
correspond to 973 cell growth inhibition rates of 28.8%, 52.3%, 65.3%, 89.8%); Western 
blotting showed the expression of intracellular Bax, Cyto c and caspase-3 protein was 
increased in aDR5scFv-treated 973 cells ; Tumor growth of aDR5scFv-treated group was 
slower than control group . Combined treatment using aDR5scFv and radiotherapy 
displayed obvious suppressive effect on 973 tumor growth as compared to single treatment 
(p<0.05). Cell apoptosis was found by HE staining and TUNNEL. Apoptosis in combined 
treatment group is the most obvious . 
CONCLUSION 
1. aDR5scFv could recognize eDR5 specifically 
2.The experiment in vitro shows that the mechanism that aDR5scFv make on the nude 
rats’ Lung cancer animal model based on this therapy may be really linked to the 
expression level of Bax，cytoc, Caspase-3 protein. 
3. The experiment in vivo shows that aDR5scFv can induce 973 cell line apoptosis 
with no significant untoward effects on normal cells. Apoptosis in combined treatment 
group of radiotherapy/ aDR5scFv is the most obvious. 
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人数的 28%，严重危害人类的健康。据估计，全球每年有 60 万左右的新患者，在
我国，肺癌的发病率一直呈上升趋势，平均每年递增 11.9%，预计到 2025 年，我国
每年新发肺癌病人数可达 100 万人，成为第一大肺癌大国。原发性肺癌（以下简称
肺癌）是我国 常见的恶性肿瘤之一。2010 年卫生统计年鉴显示，2005 年肺癌死亡
率占我国恶性肿瘤死亡率的第 1 位。 
肺癌从大体上可分为小细胞肺癌 （SCLC） 和非小细胞肺癌 (NSCLC)。其中大
部分为非小细胞肺癌，约占 80%，小细胞肺癌约占 20%。约 65%~70% 的非小细胞
肺癌在就诊时就已处于晚期。.非小细胞肺癌又细分成 3 种亚型.这些亚型的癌细胞在
大小,形状或化学构造方面都不同. 鳞状上皮细胞癌：肺癌约有 25% 至 30% 属於这
种类型.这种肺癌与吸烟有关,通常在肺部中央接近支气管处发现。 腺癌：这种类型约






乳癌和前列腺癌三种癌症的死亡人数总和还多。肺癌很少发生在 45 岁以下的人身上. 
2008 年,美国约有 215,020 个新增肺癌病例(包括小细胞和非小细胞肺癌): 114,690 
名男性,100,330 名女性.2008 年约有 161,840 人死於肺癌:90,810 名男 性,71,030 名
女性. 男性平均终身罹患肺癌的平均机率为 13 分之 1,女性则为 16 分之 1。这些数
字包括吸烟者和非吸烟者。吸烟者罹患肺癌的风险高出许多,而非吸烟者的风险较低
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